

Mei Qiu

List of Publications by Year in Descending Order

Source: <https://exaly.com/author-pdf/6576/mei-qiu-publications-by-year.pdf>

Version: 2024-04-26

This document has been generated based on the publications and citations recorded by exaly.com. For the latest version of this publication list, visit the link given above.

The third column is the impact factor (IF) of the journal, and the fourth column is the number of citations of the article.

34
papers

79
citations

5
h-index

7
g-index

39
ext. papers

157
ext. citations

4.3
avg, IF

3.56
L-index

#	Paper	IF	Citations
34	Sodium-Glucose Cotransporter-2 Inhibitors Versus Glucagon-like Peptide-1 Receptor Agonists and the Risk for Cardiovascular Outcomes in Routine Care Patients With Diabetes Across Categories of Cardiovascular Disease.. <i>Annals of Internal Medicine</i> , 2022 , 175, W3-W4	8	
33	Network meta-analysis on the efficacy and safety of upadacitinib in adolescents and adults with moderate-to-severe atopic dermatitis. <i>International Journal of Dermatology</i> , 2022 , 61, e24-e26	1.7	2
32	Network Meta-Analysis on the Effects of SGLT2 Inhibitors Versus Finerenone on Cardiorenal Outcomes in Patients With Type 2 Diabetes and Chronic Kidney Disease.. <i>Frontiers in Pharmacology</i> , 2021 , 12, 751496	5.6	0
31	Comprehensive Analysis of Adverse Events Associated With SGLT2is: A Meta-Analysis Involving Nine Large Randomized Trials.. <i>Frontiers in Endocrinology</i> , 2021 , 12, 743807	5.7	0
30	Updated network meta-analysis assessing the relative efficacy of 13 GLP-1 RA and SGLT2 inhibitor interventions on cardiorenal and mortality outcomes in type 2 diabetes. <i>European Journal of Clinical Pharmacology</i> , 2021 , 1	2.8	
29	Letter Regarding "Systematic Review of Cardiovascular Outcome Trials Using New Antidiabetic Agents in CKD Stratified by Estimated GFR". <i>Kidney International Reports</i> , 2021 , 6, 2934-2935	4.1	1
28	Safety of four SGLT2 inhibitors in three chronic diseases: A meta-analysis of large randomized trials of SGLT2 inhibitors. <i>Diabetes and Vascular Disease Research</i> , 2021 , 18, 14791641211011016	3.3	8
27	Commentary: Sodium Glucose Cotransporter 2 Inhibitors Reduce the Risk of Heart Failure Hospitalization in Patients With Type 2 Diabetes Mellitus: A Systematic Review and Meta-Analysis of Randomized Controlled Trials. <i>Frontiers in Endocrinology</i> , 2021 , 12, 664502	5.7	1
26	Impact of time factor and patient characteristics on the efficacy of PCI vs CABG for left main coronary disease: A meta-analysis. <i>Medicine (United States)</i> , 2021 , 100, e25057	1.8	2
25	Effects of SGLT2 inhibitors on cardiovascular and renal outcomes in type 2 diabetes: A meta-analysis with trial sequential analysis. <i>Medicine (United States)</i> , 2021 , 100, e25121	1.8	4
24	Do all gliflozins reduce stroke in patients with type 2 diabetes mellitus and impaired renal function?. <i>Journal of Stroke and Cerebrovascular Diseases</i> , 2021 , 30, 105799	2.8	3
23	Letter to the Editor regarding the article "SGLT2 inhibitors and cardiovascular and renal outcomes: a meta-analysis and trial sequential analysis". <i>Heart Failure Reviews</i> , 2021 , 1	5	
22	SGLT2 inhibitors should be recommended in patients with one or more of the three diseases: type 2 diabetes, chronic kidney disease, and HFrEF. <i>European Journal of Internal Medicine</i> , 2021 , 87, 102-103	3.9	
21	Does Combination Therapy With SGLT2 Inhibitors and Renin-Angiotensin System Blockers Lead to Greater Reduction in Cardiorenal Events Among Patients With Type 2 Diabetes?. <i>Frontiers in Cardiovascular Medicine</i> , 2021 , 8, 679124	5.4	3
20	Do four SGLT2 inhibitors lead to different cardiorenal benefits in type 2 diabetes, in chronic heart failure, and in chronic kidney disease?. <i>European Journal of Internal Medicine</i> , 2021 , 87, 98-99	3.9	2
19	Sotagliflozin Reduces HF Events in T2DM Regardless of Baseline Characteristics, Including HF, CKD and LVEF. <i>Cardiovascular Drugs and Therapy</i> , 2021 , 35, 1077-1078	3.9	
18	Meta-Analysis on the Safety and Cardiorenal Efficacy of SGLT2 Inhibitors in Patients Without T2DM. <i>Frontiers in Cardiovascular Medicine</i> , 2021 , 8, 690529	5.4	1

17	Association Between SGLT2is and Cardiovascular and Respiratory Diseases: A Meta-Analysis of Large Trials. <i>Frontiers in Pharmacology</i> , 2021 , 12, 724405	5.6	1
16	Comparative Efficacy of Five SGLT2i on Cardiorenal Events: A Network Meta-analysis Based on Ten CVOTs. <i>American Journal of Cardiovascular Drugs</i> , 2021 , 1	4	1
15	Comparative Efficacy of Glucagon-like Peptide 1 Receptor Agonists and Sodium Glucose Cotransporter 2 Inhibitors for Prevention of Major Adverse Cardiovascular Events in Type 2 Diabetes: A Network Meta-analysis. <i>Journal of Cardiovascular Pharmacology</i> , 2021 , 77, 34-37	3.1	4
14	Effects of SGLT2 inhibitors on cardiovascular death and all-cause death in patients with type 2 diabetes and chronic kidney disease: an updated meta-analysis including the SCORED trial. <i>Therapeutic Advances in Endocrinology and Metabolism</i> , 2021 , 12, 20420188211044945	4.5	
13	Use of SGLT2 inhibitors and occurrence of noninfectious respiratory disorders: a meta-analysis of large randomized trials of SGLT2 inhibitors. <i>Endocrine</i> , 2021 , 73, 31-36	4	4
12	Meta-analysis of the effects of four factors on the efficacy of SGLT2 inhibitors in patients with HFrEF. <i>ESC Heart Failure</i> , 2021 , 8, 1722-1724	3.7	1
11	Comparison of the risk of SGLT2is and NonSGLT2is in leading to amputation: A network meta-analysis. <i>Journal of Diabetes and Its Complications</i> , 2021 , 35, 107803	3.2	2
10	Gliflozins for the prevention of stroke in diabetes and cardiorenal diseases: A meta-analysis of cardiovascular outcome trials. <i>Medicine (United States)</i> , 2021 , 100, e27362	1.8	1
9	Comment on "SGLT-2 inhibitors reduce the risk of cerebrovascular/cardiovascular outcomes and mortality: A systematic review and meta-analysis of retrospective cohort studies". <i>Pharmacological Research</i> , 2021 , 172, 105862	10.2	2
8	Double antithrombotic therapy for prevention of bleeding and ischemic events after percutaneous coronary intervention in patients with atrial fibrillation: A meta-analysis. <i>Medicine (United States)</i> , 2021 , 100, e24188	1.8	
7	Comprehensive analysis of the safety of semaglutide in type 2 diabetes: a meta-analysis of the SUSTAIN and PIONEER trials. <i>Endocrine Journal</i> , 2021 , 68, 739-742	2.9	3
6	Is SGLT2i superior to DPP4i for primary and secondary prevention of cardiovascular diseases and death in patients with type 2 diabetes?. <i>Pharmacological Research</i> , 2021 , 174, 105878	10.2	
5	Effects of glucagon-like peptide 1 receptor agonists and sodium glucose cotransporter 2 inhibitors on major adverse cardiovascular events in type 2 diabetes by race, ethnicity, and region: A meta-analysis. <i>Medicine (United States)</i> , 2020 , 99, e23489	1.8	4
4	Do reductions in risk of cardiorenal events with SGLT2 inhibitors in type 2 diabetes vary with baseline characteristics? A meta-analysis. <i>Endocrine</i> , 2020 , 69, 688-691	4	5
3	Osteoporosis drugs for prevention of clinical fracture in white postmenopausal women: a network meta-analysis of survival data. <i>Osteoporosis International</i> , 2020 , 31, 961-971	5.3	7
2	SGLT2 inhibitors for prevention of cardiorenal events in people with type 2 diabetes without cardiorenal disease: A meta-analysis of large randomized trials and cohort studies. <i>Pharmacological Research</i> , 2020 , 161, 105175	10.2	9
1	GLP-1RAs and SGLT2is Reduce Cardiovascular Events Independent of Reductions of Systolic Blood Pressure and Body Weight: A Meta-Analysis with Meta-Regression. <i>Diabetes Therapy</i> , 2020 , 11, 2429-2440	2.6	8